EU Approves OGSIVEO for Adult Desmoid Tumor Treatment
August 18, 2025
SpringWorks Therapeutics, a subsidiary of Merck KGaA based in Darmstadt, Germany, announced that the European Commission has approved OGSIVEO for adults with progressing desmoid tumors